Detection of Rapalog-Mediated Therapeutic Response in Renal Cancer Xenografts Using 64Cu-bevacizumab ImmunoPET
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Detection of Rapalog-Mediated Therapeutic Response in Renal Cancer Xenografts Using 64Cu-bevacizumab ImmunoPET
Authors
Keywords
-
Journal
PLoS One
Volume 8, Issue 3, Pages e58949
Publisher
Public Library of Science (PLoS)
Online
2013-03-15
DOI
10.1371/journal.pone.0058949
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Anti-Angiogenic/Vascular Effects of the mTOR Inhibitor Everolimus Are Not Detectable by FDG/FLT-PET
- (2014) Michael Honer et al. Translational Oncology
- Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further Proposals
- (2014) Terence O'Reilly et al. Translational Oncology
- mTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors
- (2012) Yanjie Zhang et al. CELL CYCLE
- Differing effects of rapamycin and mTOR kinase inhibitors on protein synthesis
- (2011) Yilin Huo et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- Evaluation of64Cu-Labeled Bifunctional Chelate–Bombesin Conjugates
- (2011) Samia Ait-Mohand et al. BIOCONJUGATE CHEMISTRY
- Basic and Therapeutic Aspects of Angiogenesis
- (2011) Michael Potente et al. CELL
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- PI3K Functions in Cancer Progression, Anticancer Immunity and Immune Evasion by Tumors
- (2011) Francesco Dituri et al. Clinical & Developmental Immunology
- The rise of metal radionuclides in medical imaging: copper-64, zirconium-89 and yttrium-86
- (2011) Oluwatayo F Ikotun et al. Future Medicinal Chemistry
- Systemic Therapy for Metastatic Non–Clear-Cell Renal Cell Carcinoma: Recent Progress and Future Directions
- (2011) Simon Chowdhury et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways
- (2011) James A. McCubrey et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Molecular mechanisms and clinical applications of angiogenesis
- (2011) Peter Carmeliet et al. NATURE
- PET imaging of EGFR expression in nude mice bearing MDA-MB-468, a human breast adenocarcinoma
- (2011) Kayvan Sadri et al. NUCLEAR MEDICINE COMMUNICATIONS
- VEGF is essential for hypoxia-inducible factor-mediated neovascularization but dispensable for endothelial sprouting
- (2011) Sunday Oladipupo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mechanisms of mTOR inhibitor resistance in cancer therapy
- (2011) Jennifer S. Carew et al. Targeted Oncology
- Signaling pathways in renal cell carcinoma
- (2010) Gowrishankar Banumathy et al. CANCER BIOLOGY & THERAPY
- Positive Progress in ImmunoPET—Not Just a Coincidence
- (2010) Katelyn E. McCabe et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- VEGF-PET Imaging Is a Noninvasive Biomarker Showing Differential Changes in the Tumor during Sunitinib Treatment
- (2010) W. B. Nagengast et al. CANCER RESEARCH
- Positron emission tomography imaging and biodistribution of vascular endothelial growth factor with 64Cu-labeled bevacizumab in colorectal cancer xenografts
- (2010) Bishnuhari Paudyal et al. CANCER SCIENCE
- PET imaging of tumor angiogenesis in mice with VEGF-A-targeted 86Y-CHX-A″-DTPA-bevacizumab
- (2010) Tapan K. Nayak et al. INTERNATIONAL JOURNAL OF CANCER
- VHL and HIF signalling in renal cell carcinogenesis
- (2010) Marcella M Baldewijns et al. JOURNAL OF PATHOLOGY
- Targeted therapies in renal cell cancer: recent developments in imaging
- (2010) Astrid A. M. van der Veldt et al. Targeted Oncology
- A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer
- (2009) Robert J. Amato et al. CANCER
- 18F-FDG PET/CT Imaging for an Early Assessment of Response to Sunitinib in Metastatic Renal Carcinoma: Preliminary Study
- (2009) Laetitia Vercellino et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
- (2009) Marta Pàez-Ribes et al. CANCER CELL
- Tumor suppressors and cell metabolism: a recipe for cancer growth
- (2009) R. G. Jones et al. GENES & DEVELOPMENT
- Resistance to targeted therapy in renal-cell carcinoma
- (2009) Brian I Rini et al. LANCET ONCOLOGY
- Molecular PET and PET/CT imaging of tumour cell proliferation using F-18 fluoro-L-thymidine: a comprehensive evaluation
- (2009) Tara Barwick et al. NUCLEAR MEDICINE COMMUNICATIONS
- Origin and function of tumor stroma fibroblasts
- (2009) Georgia Xouri et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- TOR regulation of AGC kinases in yeast and mammals
- (2008) Estela Jacinto et al. BIOCHEMICAL JOURNAL
- Refractoriness to Antivascular Endothelial Growth Factor Treatment: Role of Myeloid Cells
- (2008) F. Shojaei et al. CANCER RESEARCH
- Changes in Tumor Metabolism as Readout for Mammalian Target of Rapamycin Kinase Inhibition by Rapamycin in Glioblastoma
- (2008) L. H. Wei et al. CLINICAL CANCER RESEARCH
- Macrophages define the invasive microenvironment in breast cancer
- (2008) Jeffrey W. Pollard JOURNAL OF LEUKOCYTE BIOLOGY
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now